Phototherapy of granuloma annulare: a single center retrospective study.

IF 2.7 3区 化学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY
Photochemical & Photobiological Sciences Pub Date : 2025-04-01 Epub Date: 2025-04-17 DOI:10.1007/s43630-025-00716-9
Ines Katharina Himmelstoss, Franz Josef Legat, Alexandra Gruber-Wackernagel, Peter Wolf, Angelika Hofer
{"title":"Phototherapy of granuloma annulare: a single center retrospective study.","authors":"Ines Katharina Himmelstoss, Franz Josef Legat, Alexandra Gruber-Wackernagel, Peter Wolf, Angelika Hofer","doi":"10.1007/s43630-025-00716-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Granuloma annulare is a chronic, benign skin condition characterized by small erythematous patches, plaques or papules in annular or disseminated order. Due to the cosmetic impact, many patients experience a significant level of distress. Nevertheless, selecting the optimal treatment method often poses a challenge due to the limited available data. A remission of skin lesions can be achieved through topical, systemic, or intralesional therapies, and various forms of phototherapy.</p><p><strong>Patients and methodology: </strong>This retrospective study included 58 patients diagnosed with granuloma annulare and evaluated a total of 73 cycles of phototherapy (UVA-1, oral-PUVA, bath-PUVA) concerning treatment response and adverse events. It was conducted at the outpatient phototherapy clinic of the University Department for Dermatology and Venereology, Medical University of Graz. The Data was collected over the period from February 2011 and February 2021.</p><p><strong>Results: </strong>Complete response was achieved in 37.5% of the 16 bath-PUVA therapy cycles, 25.7% of the 35 oral-PUVA therapy cycles, and 35.3% of the 17 UVA-1 therapy cycles. Partial response was noted in 62.5% of the oral-PUVA therapies, 50% of the bath-PUVA therapies, and 41.2% of the UVA-1 therapies. Generally, the adverse events of phototherapy were mild, with the highest incidence of adverse events associated with oral-PUVA and the lowest with UVA-1 therapy.</p><p><strong>Conclusions: </strong>No significant differences in efficacy were found between UVA-1 therapy, oral-PUVA, and bath-PUVA. However, UVA-1 therapy resulted in the fewest adverse events. Given the frequent occurrence of recurrences, the risk-benefit profile of each therapy should be carefully assessed in advance.</p>","PeriodicalId":98,"journal":{"name":"Photochemical & Photobiological Sciences","volume":"24 4","pages":"651-658"},"PeriodicalIF":2.7000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Photochemical & Photobiological Sciences","FirstCategoryId":"92","ListUrlMain":"https://doi.org/10.1007/s43630-025-00716-9","RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/17 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Granuloma annulare is a chronic, benign skin condition characterized by small erythematous patches, plaques or papules in annular or disseminated order. Due to the cosmetic impact, many patients experience a significant level of distress. Nevertheless, selecting the optimal treatment method often poses a challenge due to the limited available data. A remission of skin lesions can be achieved through topical, systemic, or intralesional therapies, and various forms of phototherapy.

Patients and methodology: This retrospective study included 58 patients diagnosed with granuloma annulare and evaluated a total of 73 cycles of phototherapy (UVA-1, oral-PUVA, bath-PUVA) concerning treatment response and adverse events. It was conducted at the outpatient phototherapy clinic of the University Department for Dermatology and Venereology, Medical University of Graz. The Data was collected over the period from February 2011 and February 2021.

Results: Complete response was achieved in 37.5% of the 16 bath-PUVA therapy cycles, 25.7% of the 35 oral-PUVA therapy cycles, and 35.3% of the 17 UVA-1 therapy cycles. Partial response was noted in 62.5% of the oral-PUVA therapies, 50% of the bath-PUVA therapies, and 41.2% of the UVA-1 therapies. Generally, the adverse events of phototherapy were mild, with the highest incidence of adverse events associated with oral-PUVA and the lowest with UVA-1 therapy.

Conclusions: No significant differences in efficacy were found between UVA-1 therapy, oral-PUVA, and bath-PUVA. However, UVA-1 therapy resulted in the fewest adverse events. Given the frequent occurrence of recurrences, the risk-benefit profile of each therapy should be carefully assessed in advance.

光疗环形肉芽肿:单中心回顾性研究。
背景:环状肉芽肿是一种慢性、良性皮肤疾病,以环状或弥散性小红斑斑块、斑块或丘疹为特征。由于对美容的影响,许多患者经历了相当程度的痛苦。然而,由于可用的数据有限,选择最佳的治疗方法往往是一个挑战。皮肤病变的缓解可以通过局部、全身或局内治疗以及各种形式的光疗来实现。患者和方法:本回顾性研究纳入了58例诊断为环形肉芽肿的患者,并评估了总共73个光疗周期(UVA-1、口服- puva、沐浴- puva)的治疗反应和不良事件。该研究在格拉茨医科大学皮肤病和性病学系的门诊光疗诊所进行。数据收集于2011年2月至2021年2月期间。结果:16个沐浴- puva治疗周期中37.5%达到完全缓解,35个口服- puva治疗周期中25.7%达到完全缓解,17个UVA-1治疗周期中35.3%达到完全缓解。62.5%的口服puva治疗、50%的沐浴治疗和41.2%的UVA-1治疗出现部分缓解。一般来说,光疗的不良事件是轻微的,与口服puva相关的不良事件发生率最高,与UVA-1治疗相关的不良事件发生率最低。结论:UVA-1治疗、口服puva治疗和浴用puva治疗的疗效无显著差异。然而,UVA-1治疗导致的不良事件最少。鉴于复发的频繁发生,应事先仔细评估每种治疗的风险-收益概况。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Photochemical & Photobiological Sciences
Photochemical & Photobiological Sciences 生物-生化与分子生物学
CiteScore
5.60
自引率
6.50%
发文量
201
审稿时长
2.3 months
期刊介绍: A society-owned journal publishing high quality research on all aspects of photochemistry and photobiology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信